Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$57.18 - $84.43 $16.6 Million - $24.5 Million
-290,000 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$47.86 - $83.95 $13.9 Million - $24.3 Million
290,000 New
290,000 $24.3 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $76.5M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Cloud Alpha Capital Management Limited Portfolio

Follow Cloud Alpha Capital Management Limited and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cloud Alpha Capital Management Limited, based on Form 13F filings with the SEC.

News

Stay updated on Cloud Alpha Capital Management Limited with notifications on news.